Literature DB >> 35588331

Identification of high-risk stage I colon and rectal cancer patients: a retrospective analysis of a large Japanese cohort.

Yudai Fukui1, Koya Hida2, Nobuaki Hoshino1, Daisuke Nishizaki1, Ryosuke Okamura1, Shinichi Yamauchi3, Kenichi Sugihara4, Yoshiharu Sakai1,5.   

Abstract

PURPOSE: Data regarding risk factors for recurrence in stage I colorectal cancer patients are limited. The aim of this study was to clarify the existence of a high-recurrence-risk population among stage I colorectal cancer patients.
METHODS: This analysis included 7,539 stage I colorectal cancer patients treated between 1997 and 2012 at 24 leading hospitals in Japan. Risk factors for time to recurrence were evaluated using a Cox proportional hazards model, and a high-risk group for recurrence was identified. Prognostic outcomes of high-risk stage I colorectal cancer patients were compared with those of low-risk stage I and stage II patients.
RESULTS: Multivariable analyses identified left-sided location (hazard ratio [HR]: 1.65, 95% confidence interval [CI]: 1.09-2.58), T2 tumors (HR: 1.80, 95% CI: 1.21-2.66), and lymphatic invasion (HR: 1.55, 95% CI: 1.05-2.28) as risk factors for recurrence in stage I colon cancer, and patients with these three risk factors were classified as high risk. For stage I rectal cancer, patients with poor differentiation (HR: 2.86, 95% CI: 1.21-5.69), T2 tumors (HR: 1.53, 95% CI: 1.07-2.23), and venous invasion (HR: 1.51, 95% CI: 1.08-2.13) were identified as high risk. The Kaplan-Meier analysis of cumulative recurrence rate and recurrence-free survival revealed that the high-risk stage I colorectal cancer patients have poorer clinical outcomes than the low-risk patients.
CONCLUSION: Although stage I colorectal cancer patients generally have a favorable prognosis after curative surgery, poorer prognosis was observed in high-risk stage I colorectal cancer patients than in low-risk patients.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Colorectal cancer; High risk; Recurrence; Stage I

Mesh:

Year:  2022        PMID: 35588331     DOI: 10.1007/s00384-022-04161-3

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.796


  22 in total

1.  Survival after recurrence of stage I-III breast, colorectal, or lung cancer.

Authors:  Michael J Hassett; Hajime Uno; Angel M Cronin; Nikki M Carroll; Mark C Hornbrook; Paul Fishman; Debra P Ritzwoller
Journal:  Cancer Epidemiol       Date:  2017-07-12       Impact factor: 2.984

2.  Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study.

Authors:  Hirotoshi Kobayashi; Hidetaka Mochizuki; Kenichi Sugihara; Takayuki Morita; Kenjiro Kotake; Tatsuo Teramoto; Shingo Kameoka; Yukio Saito; Keiichi Takahashi; Kazuo Hase; Masatoshi Oya; Koutarou Maeda; Takashi Hirai; Masao Kameyama; Kazuo Shirouzu; Tetsuichiro Muto
Journal:  Surgery       Date:  2006-09-14       Impact factor: 3.982

3.  Recent trends in colorectal cancer mortality in Europe.

Authors:  Cristina Bosetti; Fabio Levi; Valentina Rosato; Paola Bertuccio; Franca Lucchini; Eva Negri; Carlo La Vecchia
Journal:  Int J Cancer       Date:  2010-11-16       Impact factor: 7.396

Review 4.  Worldwide variations in colorectal cancer.

Authors:  Melissa M Center; Ahmedin Jemal; Robert A Smith; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2009 Nov-Dec       Impact factor: 508.702

5.  Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy.

Authors:  Ralf Gertler; Robert Rosenberg; Tibor Schuster; Helmut Friess
Journal:  Eur J Cancer       Date:  2009-08-12       Impact factor: 9.162

6.  Global patterns and trends in colorectal cancer incidence and mortality.

Authors:  Melina Arnold; Mónica S Sierra; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  Gut       Date:  2016-01-27       Impact factor: 23.059

7.  Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement.

Authors:  Jeffrey A Meyerhardt; Pamela B Mangu; Patrick J Flynn; Larissa Korde; Charles L Loprinzi; Bruce D Minsky; Nicholas J Petrelli; Kim Ryan; Deborah H Schrag; Sandra L Wong; Al B Benson
Journal:  J Clin Oncol       Date:  2013-11-12       Impact factor: 44.544

Review 8.  Colorectal cancer.

Authors:  Hermann Brenner; Matthias Kloor; Christian Peter Pox
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

9.  Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution.

Authors:  Konosuke Moritani; Hirotoshi Hasegawa; Koji Okabayashi; Yoshiyuki Ishii; Takashi Endo; Yuko Kitagawa
Journal:  Surg Today       Date:  2013-10-16       Impact factor: 2.549

10.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Kei Muro; Yoichi Ajioka; Yojiro Hashiguchi; Yoshinori Ito; Yutaka Saito; Tetsuya Hamaguchi; Hideyuki Ishida; Megumi Ishiguro; Soichiro Ishihara; Yukihide Kanemitsu; Hiroshi Kawano; Yusuke Kinugasa; Norihiro Kokudo; Keiko Murofushi; Takako Nakajima; Shiro Oka; Yoshiharu Sakai; Akihito Tsuji; Keisuke Uehara; Hideki Ueno; Kentaro Yamazaki; Masahiro Yoshida; Takayuki Yoshino; Narikazu Boku; Takahiro Fujimori; Michio Itabashi; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Yasuhiro Shimada; Keiichi Takahashi; Shinji Tanaka; Osamu Tsuruta; Toshiharu Yamaguchi; Naohiko Yamaguchi; Toshiaki Tanaka; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2017-03-27       Impact factor: 3.402

View more
  1 in total

1.  Letter to the Editor regarding the identification of high‑risk stage I colon and rectal cancer patients: a retrospective analysis of a large Japanese cohort.

Authors:  Sung Hwan Hwang; Jun Ho Lee
Journal:  Int J Colorectal Dis       Date:  2022-08-11       Impact factor: 2.796

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.